<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27114074</article-id><article-id pub-id-type="pmc">4845347</article-id><article-id pub-id-type="publisher-id">2321</article-id><article-id pub-id-type="doi">10.1186/s12885-016-2321-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Baertsch</surname><given-names>Marc-Andrea</given-names></name><address><email>marc-andrea.baertsch@med.uni-heidelberg.de</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Schlenzka</surname><given-names>Jana</given-names></name><address><email>Jana.Schlenzka@med.uni-heidelberg.de</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Mai</surname><given-names>Elias K.</given-names></name><address><email>Elias.Mai@med.uni-heidelberg.de</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Merz</surname><given-names>Maximilian</given-names></name><address><email>Maximilian.Merz@med.uni-heidelberg.de</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Hillenga&#x000df;</surname><given-names>Jens</given-names></name><address><email>Jens.Hillengass@med.uni-heidelberg.de</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Raab</surname><given-names>Marc S.</given-names></name><address><email>Marc.Raab@med.uni-heidelberg.de</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Hose</surname><given-names>Dirk</given-names></name><address><email>Dirk.Hose@med.uni-heidelberg.de</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Wuchter</surname><given-names>Patrick</given-names></name><address><email>Patrick.Wuchter@med.uni-heidelberg.de</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Ho</surname><given-names>Anthony D.</given-names></name><address><email>Anthony.Ho@med.uni-heidelberg.de</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Jauch</surname><given-names>Anna</given-names></name><address><email>Anna.Jauch@med.uni-heidelberg.de</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Hielscher</surname><given-names>Thomas</given-names></name><address><email>t.hielscher@Dkfz-Heidelberg.de</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Kunz</surname><given-names>Christina</given-names></name><address><email>C.Kunz@Dkfz-Heidelberg.de</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Luntz</surname><given-names>Steffen</given-names></name><address><email>Steffen.Luntz@med.uni-heidelberg.de</email></address><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Klein</surname><given-names>Stefan</given-names></name><address><email>stefan.klein@umm.de</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Schmidt-Wolf</surname><given-names>Ingo G. H.</given-names></name><address><email>Ingo.Schmidt-Wolf@ukb.uni-bonn.de</email></address><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Goerner</surname><given-names>Martin</given-names></name><address><email>martin.goerner@klinikumbielefeld.de</email></address><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Schmidt-Hieber</surname><given-names>Martin</given-names></name><address><email>martin.schmidt-hieber@helios-kliniken.de</email></address><xref ref-type="aff" rid="Aff8"/></contrib><contrib contrib-type="author"><name><surname>Reimer</surname><given-names>Peter</given-names></name><address><email>p.reimer@kliniken-essen-sued.de</email></address><xref ref-type="aff" rid="Aff9"/></contrib><contrib contrib-type="author"><name><surname>Graeven</surname><given-names>Ullrich</given-names></name><address><email>Ullrich.Graeven@mariahilf.de</email></address><xref ref-type="aff" rid="Aff10"/></contrib><contrib contrib-type="author"><name><surname>Fenk</surname><given-names>Roland</given-names></name><address><email>Fenk@med.uni-duesseldorf.de</email></address><xref ref-type="aff" rid="Aff11"/></contrib><contrib contrib-type="author"><name><surname>Salwender</surname><given-names>Hans</given-names></name><address><email>h.salwender@asklepios.com</email></address><xref ref-type="aff" rid="Aff12"/></contrib><contrib contrib-type="author"><name><surname>Scheid</surname><given-names>Christof</given-names></name><address><email>c.scheid@uni-koeln.de</email></address><xref ref-type="aff" rid="Aff13"/></contrib><contrib contrib-type="author"><name><surname>Nogai</surname><given-names>Axel</given-names></name><address><email>axel.nogai@charite.de</email></address><xref ref-type="aff" rid="Aff14"/></contrib><contrib contrib-type="author"><name><surname>Haenel</surname><given-names>Mathias</given-names></name><address><email>m.haenel@skc.de</email></address><xref ref-type="aff" rid="Aff15"/></contrib><contrib contrib-type="author"><name><surname>Lindemann</surname><given-names>Hans W.</given-names></name><address><email>w.lindemann@kkh-hagen.de</email></address><xref ref-type="aff" rid="Aff16"/></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Hans</given-names></name><address><email>H.Martin@em.uni-frankfurt.de</email></address><xref ref-type="aff" rid="Aff17"/></contrib><contrib contrib-type="author"><name><surname>Noppeney</surname><given-names>Richard</given-names></name><address><email>Richard.Noppeney@uk-essen.de</email></address><xref ref-type="aff" rid="Aff18"/></contrib><contrib contrib-type="author"><name><surname>Weisel</surname><given-names>Katja</given-names></name><address><email>katja.weisel@med.uni-tuebingen.de</email></address><xref ref-type="aff" rid="Aff19"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Goldschmidt</surname><given-names>Hartmut</given-names></name><address><email>Hartmut.Goldschmidt@med.uni-heidelberg.de</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff20"/></contrib><aff id="Aff1"><label/>Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany </aff><aff id="Aff2"><label/>Institute for Human Genetics, University of Heidelberg, Heidelberg, Germany </aff><aff id="Aff3"><label/>Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany </aff><aff id="Aff4"><label/>Coordination Centre for Clinical Trials (KKS), University Hospital Heidelberg, Heidelberg, Germany </aff><aff id="Aff5"><label/>Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany </aff><aff id="Aff6"><label/>Center for Integrated Oncology, Med. Klinik und Poliklinik III, University Hospital Bonn, Bonn, Germany </aff><aff id="Aff7"><label/>Hematology, Oncology and Palliative Care, Community Hospital Bielefeld, Bielefeld, Germany </aff><aff id="Aff8"><label/>Hematology and Oncology, Helios-Hospital Berlin Buch, Berlin, Germany </aff><aff id="Aff9"><label/>Hematology, Oncology and Stem Cell Transplantation, Evangelisches Krankenhaus Essen-Werden gGmbH, Essen, Germany </aff><aff id="Aff10"><label/>Hematology, Oncology and Gastroenterology, Maria-Hilf-Krankenhaus, M&#x000f6;nchengladbach, Germany </aff><aff id="Aff11"><label/>Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Duesseldorf, Germany </aff><aff id="Aff12"><label/>Hematology, Oncology and Palliative Care, Asklepios Klinik Altona, Hamburg, Germany </aff><aff id="Aff13"><label/>Department I of Internal Medicine, University of Cologne, Cologne, Germany </aff><aff id="Aff14"><label/>Internal Medicine III, Charit&#x000e9; Campus Benjamin Franklin, Berlin, Germany </aff><aff id="Aff15"><label/>Hematology, Oncology and Stem Cell Transplantation, Klinikum Chemnitz GmbH, Chemnitz, Germany </aff><aff id="Aff16"><label/>Hematology and Oncology, Kath. Krankenhaus Hagen gem. GmbH - St.-Marien-Hospital, Hagen, Germany </aff><aff id="Aff17"><label/>Hematology and Oncology, Goethe University, Frankfurt, Germany </aff><aff id="Aff18"><label/>Hematology, University Hospital Essen, Essen, Germany </aff><aff id="Aff19"><label/>Hematology, Oncology and Immunology, University of Tuebingen, Tuebingen, Germany </aff><aff id="Aff20"><label/>National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>4</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>4</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>16</volume><elocation-id>290</elocation-id><history><date date-type="received"><day>10</day><month>9</month><year>2015</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; Baertsch et al. 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Despite novel therapeutic agents, most multiple myeloma (MM) patients eventually relapse. Two large phase III trials have shown significantly improved response rates (RR) of lenalidomide/dexamethasone compared with placebo/dexamethasone in relapsed MM (RMM) patients. These results have led to the approval of lenalidomide for RMM patients and lenalidomide/dexamethasone has since become a widely accepted second-line treatment. Furthermore, in RMM patients consolidation with high-dose chemotherapy plus autologous stem cell transplantation has been shown to significantly increase progression free survival (PFS) as compared to cyclophosphamide in a phase III trial. The randomized prospective ReLApsE trial is designed to evaluate PFS after lenalidomide/dexamethasone induction, high-dose chemotherapy consolidation plus autologous stem cell transplantation and lenalidomide maintenance compared with the well-established lenalidomide/dexamethasone regimen in RMM patients.</p></sec><sec><title>Methods/Design</title><p>ReLApsE is a randomized, open, multicenter phase III trial in a planned study population of 282 RMM patients. All patients receive three lenalidomide/dexamethasone cycles and - in absence of available stem cells from earlier harvesting - undergo peripheral blood stem cell mobilization and harvesting. Subsequently, patients in arm A continue on consecutive lenalidomide/dexamethasone cycles, patients in arm B undergo high dose chemotherapy plus autologous stem cell transplantation followed by lenalidomide maintenance until discontinuation criteria are met. Therapeutic response is evaluated after the 3<sup>rd</sup> (arm A&#x02009;+&#x02009;B) and the 5<sup>th</sup> lenalidomide/dexamethasone cycle (arm A) or 2&#x000a0;months after autologous stem cell transplantation (arm B) and every 3&#x000a0;months thereafter (arm A&#x02009;+&#x02009;B). After finishing the study treatment, patients are followed up for survival and subsequent myeloma therapies. The expected trial duration is 6.25&#x000a0;years from first patient in to last patient out. The primary endpoint is PFS, secondary endpoints include overall survival (OS), RR, time to best response and the influence of early versus late salvage high dose chemotherapy plus autologous stem cell transplantation on OS.</p></sec><sec><title>Discussion</title><p>This phase III trial is designed to evaluate whether high dose chemotherapy plus autologous stem cell transplantation and lenalidomide maintenance after lenalidomide/dexamethasone induction improves PFS compared with the well-established continued lenalidomide/dexamethasone regimen in RMM patients. Trial registration: ISRCTN16345835 (date of registration 2010-08-24).</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s12885-016-2321-2) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Multiple myeloma</kwd><kwd>Relapse</kwd><kwd>Second-line treatment</kwd><kwd>Lenalidomide</kwd><kwd>Autologous stem cell transplantation</kwd><kwd>High-dose chemotherapy</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/http://dx.doi.org/10.13039/100006436</institution-id><institution>Celgene (US)</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/http://dx.doi.org/10.13039/100002429</institution-id><institution>Amgen (US)</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution>Chugai</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>With an incidence rate of 5-6/100.000, multiple myeloma (MM) accounts for 13&#x000a0;% of hematologic cancers and 1&#x000a0;% of all neoplastic diseases in Western countries [<xref ref-type="bibr" rid="CR1">1</xref>]. In first-line treatment of MM, high-dose chemotherapy (HDCT) with subsequent autologous stem-cell transplantation (ASCT) has become the standard of care in eligible patients [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. In recent years patient outcomes have been further improved by the introduction of novel agents, namely immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) into first-line therapy. Nevertheless, MM remains largely incurable and almost all patients eventually relapse. Therapeutic options in the setting of relapsed MM (RMM) include salvage HDCT/ASCT, novel agents (IMiDs, PIs, agents under clinical investigation), chemotherapy, corticosteroids, and allogeneic stem cell transplantation [<xref ref-type="bibr" rid="CR4">4</xref>]. In the absence of an established standard of care the selection of a suitable treatment regimen for RMM patients is usually based on disease- and patient-specific factors such as regimens employed in and response to prior lines of therapy. Again, the introduction of IMIDs and proteasome inhibitors into the treatment of RMM has led to a major increase in survival rates of this patient population [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>].</p><p>Lenalidomide is an orally administered IMiD and a derivative of the structurally related thalidomide [<xref ref-type="bibr" rid="CR12">12</xref>]. The mechanism of action of lenalidomide is multifaceted [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>] including apoptosis induction, alteration of the interaction of myeloma cells with bone marrow stroma [<xref ref-type="bibr" rid="CR15">15</xref>], antiangiogenesis [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], and immunomodulation [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. More recently, anti-myeloma activity of lenalidomide has been shown to depend on interaction with cereblon, a protein involved in the teratogenicity of thalidomide [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>]. Two pivotal phase III trials (MM-009 and MM-010) have demonstrated highly significant improvement of response rates with lenalidomide/dexamethasone compared with placebo/dexamethasone in a total of 704 RMM patients and subsequently led to regulatory approval of lenalidomide in the USA and the EU. All patients in these pivotal trials received 40&#x000a0;mg dexamethasone on days 1&#x02013;4, 9&#x02013;12 and 17&#x02013;20 and either 25&#x000a0;mg lenalidomide or placebo on days 1&#x02013;21 of 28-day cycles. After completion of the 4<sup>th</sup> cycle, dexamethasone was limited to days 1&#x02013;4 [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Pooled analysis of both registration studies revealed superior overall response rate (ORR; 60.6&#x000a0;% vs. 21.9&#x000a0;%), time to progression (TTP; 13.4 vs. 4.6&#x000a0;months) and median OS (38.0 vs. 31.6&#x000a0;months) of the lenalidomide-containing regimen, but also significantly more adverse events (AEs), especially grade 3&#x02013;4 neutropenia (35.4&#x000a0;% vs. 3.4&#x000a0;%) and thromboembolic events (15.9&#x000a0;% vs. 5.4&#x000a0;%) [<xref ref-type="bibr" rid="CR23">23</xref>]. Dexamethasone dosing was subject of investigation in a phase III trial in NDMM patients. In combination with lenalidomide, high-dose dexamethasone (480&#x000a0;mg/cycle; 40&#x000a0;mg on days 1&#x02013;4, 9&#x02013;12 and 17&#x02013;20) led to significantly increased ORR (79&#x000a0;% vs. 68&#x000a0;%), but low dose-dexamethasone (160&#x000a0;mg/cycle; 40&#x000a0;mg on days 1, 8, 15, 22) showed significantly increased OS after 1 and 2&#x000a0;years (96&#x000a0;% vs. 87&#x000a0;% and 87&#x000a0;% vs. 75&#x000a0;%, respectively). This was related to a significantly lower incidence of AEs including infectious and thromboembolic events and deaths in the low-dose dexamethasone arm [<xref ref-type="bibr" rid="CR24">24</xref>]. A subgroup analysis of RMM patients from MM-009 and MM-010 with dexamethasone dose reduction confirmed these results [<xref ref-type="bibr" rid="CR25">25</xref>]. Furthermore, lenalidomide maintenance treatment has been evaluated in four phase III trials in NDMM patients [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>]. While PFS after lenalidomide maintenance was markedly prolonged in all four trials, OS was significantly superior in only one trial [<xref ref-type="bibr" rid="CR30">30</xref>]. Despite the finding of an increased incidence of second primary malignancies in the maintenance arm, the odds for lower mortality are in favor of lenalidomide maintenance treatment [<xref ref-type="bibr" rid="CR31">31</xref>].</p><p>Available data on HDCT/ASCT in RMM patients largely comes from retrospective, non-randomized, single-center or registry-based studies [<xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR45">45</xref>] and few prospective trials of early (i.e. first-line) vs. delayed (i.e. second-line) HDCT/ASCT [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. These studies suggest that salvage HDCT/ASCT is feasible in RMM patients considered eligible based on sufficient general condition and absence of prohibitive comorbidities. However, reported outcomes vary due to small and/or heterogeneous patient populations and differing salvage regimens. A recently published review of 19 retrospective studies of salvage HDCT/ASCT in patients treated with first-line HDCT/ASCT reported median ORR of 64.3&#x000a0;% (range 27.3 to 97.4&#x000a0;%), median PFS of 12.3&#x000a0;months (range 6 to 36&#x000a0;months), median OS of 32.4&#x000a0;months (range 8 to 79.1&#x000a0;months) and median transplantation associated mortality (TRM) of 4.1&#x000a0;% (range 0 to 22&#x000a0;%). TTP after first-line HDCT/ASCT of&#x02009;&#x02265;&#x02009;19.8&#x000a0;months (range 6 to 36&#x000a0;months) was identified as the major predictive factor for a beneficial outcome after salvage HDCT/ASCT. Furthermore, the quality of response after first-line HDCT/ASCT and the number of prior lines of therapy were suggested as predictive factors [<xref ref-type="bibr" rid="CR48">48</xref>]. A similar, retrospective study from our center involving 200 patients treated between 1995 and 2010 with salvage HDCT/ASCT at relapse after first-line HDCT/ASCT yielded comparable results with median ORR of 80.4&#x000a0;%, median PFS of 15.4&#x000a0;months, median OS of 42.3&#x000a0;months and TRM of 3&#x000a0;%. An overall survival advantage for patients treated with bortezomib or lenalidomide during reinduction suggested that salvage HDCT/ASCT and novel agents are complementary treatment approaches. Moreover, a favorable cytogenetic status (i.e. absence of +1q21, del(17p13) and t(4;14)) was associated with significantly prolonged PFS (25.6 vs. 13.2&#x000a0;months) [<xref ref-type="bibr" rid="CR41">41</xref>]. Recently, results from the first prospective, randomized trial on salvage HDCT/ASCT in patients with a previous HDCT/ASCT have been published [<xref ref-type="bibr" rid="CR49">49</xref>]. At first relapse at least 18&#x000a0;months (later reduced to 12&#x000a0;months) after previous HDCT/ASCT, 293 patients were treated with bortezomib/doxorubicin/dexamethasone (PAD) reinduction therapy and underwent stem cell mobilization and harvesting if applicable. Subsequently, 174 eligible patients were randomized on a 1:1 basis to receive either HDCT (melphalan 200&#x000a0;mg/m<sup>2</sup>) and ASCT or cyclophosphamide (400&#x000a0;mg/m<sup>2</sup> per week for 12&#x000a0;weeks) consolidation therapy. ORR in the HDCT/ASCT arm was 83&#x000a0;% compared with 75&#x000a0;% in the cyclophosphamide arm with significantly more very good partial remissions or better after HDCT/ASCT (60&#x000a0;% vs. 47&#x000a0;%). The primary endpoint of median TTP was significantly prolonged (19 vs. 11&#x000a0;months). OS did not differ significantly with median OS not having been reached at the cut off date for the final analysis and 3-year OS of 80.3&#x000a0;% vs. 62.9&#x000a0;%. TRM was 1&#x000a0;% in the HDCT/ASCT arm. A subgroup with an unfavorable cytogenetic status (i.e. t(4;14), t(14;16) and/or del(17p13)) did not benefit from HDCT/ASCT (hazard ratio (HR) 2.41). However, the low proportion of patients with available cytogenetic data (51&#x000a0;% of patients undergoing randomization) and the low number of patients with an unfavorable cytogenetic status (<italic>n</italic>&#x02009;=&#x02009;13; 15&#x000a0;%) limit the interpretation of this finding.</p><p>Existing evidence suggests both feasibility and benefit of salvage HDCT/ASCT in eligible RMM patients. Moreover, novel agent based regimens and HDCT/ASCT seem to be complementary salvage treatment approaches. The ReLApsE trial is designed to analyze the benefit of salvage HDCT/ASCT incorporated into the widely used and novel agent based salvage treatment lenalidomide/dexamethasone (Rd) in a prospective, randomized setting.</p></sec><sec id="Sec2"><title>Methods/Design</title><sec id="Sec3"><title>Design</title><p>ReLApsE is a randomized, controlled, open-label, multicenter phase III trial in a planned study population of 282 RMM patients in their 1<sup>st</sup> to 3<sup>rd</sup> relapse. Patients are randomized 1:1 to receive either Rd reinduction, HDCT/ASCT and lenalidomide maintenance or continued Rd. Patients are stratified according to study site and HDCT/ASCT during first-line therapy (yes vs. no). The protocol published here is based on the full protocol version 4.0 as of 2014-04-15.</p></sec><sec id="Sec4"><title>Trial objectives</title><sec id="Sec5"><title>Primary objective</title><p>PFS is defined as time from randomization to progressive disease (PD) or death, irrespective of the cause of death, and is evaluated as primary objective. Patients that are event-free at the time of analysis are censored at the date of the last response evaluation.</p></sec><sec id="Sec6"><title>Secondary objectives</title><p>Secondary objectives are: OS; response rates to Rd, HDCT/ASCT and lenalidomide maintenance; time to best response; impact of complete response (CR) and very good partial response (VGPR) prior to HDCT/ASCT and prior to lenalidomide maintenance on PFS and OS; impact of early salvage HDCT/ASCT with subsequent lenalidomide maintenance versus late salvage HDCT/ASCT (performed as a post-study treatment) on OS; feasibility of stem cell mobilization and apheresis; safety and toxicity (type, frequency, CTC grading, causality of AEs); time to initiation of next anti-myeloma treatment.</p></sec></sec><sec id="Sec7"><title>Setting</title><p>ReLApsE is an investigator initiated trial designed and carried out by the German-Speaking Myeloma Multicenter Group (GMMG). The trial setting is multicentric with 16 participating study sites located in Germany: Helios Hospital Berlin-Buch; Charit&#x000e9; Campus Benjamin Franklin, Berlin; Community Hospital Bielefeld; University Hospital Bonn; Klinikum Chemnitz GmbH; University Hospital D&#x000fc;sseldorf; University Hospital Essen; Evangelisches Krankenhaus Essen-Werden gGmbH; Goethe University, Frankfurt; Katholisches Krankenhaus Hagen gGmbH; Asklepios Klinik Altona, Hamburg; Heidelberg University Hospital (trial sponsor); University Hospital Cologne; University Hospital Mannheim; Maria-Hilf-Krankenhaus M&#x000f6;nchengladbach; University Hospital T&#x000fc;bingen.</p></sec><sec id="Sec8"><title>Estimated timeline</title><p>Recruitment of study patients was initiated during the 4<sup>th</sup> quarter of 2010 (first patient in; FPI) and is planned to be completed during the 4<sup>th</sup> quarter of 2015 (last patient in; LPI). The trial is planned to be finished during the 1<sup>st</sup> quarter of 2017 (last patient out; LPO), 1.25&#x000a0;years after LPI. An interim analysis is planned after 96 PFS relevant events. The final report is scheduled for the 1<sup>st</sup> quarter of 2018. Patients with continued benefit from treatment at the end of the trial will be allowed to continue treatment. For patients in arm B receiving maintenance lenalidomide at the end of the trial, Celgene provides lenalidomide until disease progression at no cost.</p></sec><sec id="Sec9"><title>Ethical aspects, informed consent, and safety</title><p>All study procedures are in accordance with International Conference on Harmonization of good clinical practice (ICH-GCP) guidelines, the declaration of Helsinki, and German laws, regulations and organizations. Documented approval from the ethics committees/institutional review boards (IRB) of the Medical Faculty of the Heidelberg University (main IRB) and all participating study sites has been obtained prior to study start and a data safety monitoring board (DSMB) has been installed to monitor the trial.</p><p>Written informed consent from each patient is obtained before any study-specific procedures are performed. Study participation and date of informed consent are documented in each patient&#x02019;s files.</p><p>AEs are recorded in the patient&#x02019;s case report form and relatedness to the study medication, intensity (according to CTCAE v4.03) and severity are classified. Serious AEs (SAEs) are recorded on an additional SAE form and are reported to the responsible safety officer within 24&#x000a0;h of detection. Suspected unexpected serious adverse reactions (SUSARs) are reported to the responsible ethics committee, the federal authorities and all investigators.</p><p>Due to the teratogenicity of lenalidomide a pregnancy prevention program was implemented.</p></sec><sec id="Sec10"><title>Selection of trial patients</title><p>Inclusion and exclusion criteria are listed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Inclusion and exclusion criteria</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>
<italic>Inclusion criteria</italic>
</td></tr><tr><td>&#x02022; Understanding of the nature and consequences of the trial and voluntary signature of the informed consent document</td></tr><tr><td>&#x02022; Age&#x02009;&#x02265;&#x02009;18 and&#x02009;&#x02264;&#x02009;75&#x000a0;years at the time of consent and randomization</td></tr><tr><td>&#x02022; Availability of stem cells from earlier harvesting if age&#x02009;&#x02265;&#x02009;71&#x000a0;years</td></tr><tr><td>&#x02022; 1<sup>st</sup> to 3<sup>rd</sup> relapse of symptomatic MM (according to IMWG criteria [<xref ref-type="bibr" rid="CR51">51</xref>])</td></tr><tr><td>&#x02022; Salmon and Durie stage [<xref ref-type="bibr" rid="CR58">58</xref>] II or III</td></tr><tr><td>&#x02022; Duration of response&#x02009;&#x02265;&#x02009;12&#x000a0;months in case of first-line HDCT/ASCT</td></tr><tr><td>&#x02022; WHO performance status (WHO PS)&#x02009;&#x02264;&#x02009;2</td></tr><tr><td>&#x02022; Laboratory findings within the following ranges<break/>&#x025cb; Absolute neutrophil count&#x02009;&#x02265;&#x02009;1/nl<break/>&#x025cb; Platelet count&#x02009;&#x02265;&#x02009;75/nl (depending on bone marrow infiltration with myeloma cells, platelet count&#x02009;&#x02265;&#x02009;30/nl may be acceptable)<break/>&#x025cb; Creatinine clearance&#x02009;&#x02265;&#x02009;30&#x000a0;ml/min<break/>&#x025cb; Total bilirubin&#x02009;&#x02264;&#x02009;2 x the upper limit of normal (ULN; except for elevations caused by MM)<break/>&#x025cb; Alanine aminotransferase (ALT)&#x02009;&#x02264;&#x02009;3 x ULN (except for elevations caused by MM)</td></tr><tr><td>&#x02022; Absence of malignant diseases other than MM for&#x02009;&#x02265;&#x02009;5&#x000a0;years (except basal-cell carcinoma and carcinoma in situ of the skin, the cervix and the breast)</td></tr><tr><td>&#x02022; Ability to apply thrombosis prophylaxis</td></tr><tr><td>&#x02022; Consent to all protocol requirements, especially those regarding the trial visit schedule and the pregnancy prevention program</td></tr><tr><td>
<italic>Exclusion criteria</italic>
</td></tr><tr><td>&#x02022; Pregnant or breastfeeding female</td></tr><tr><td>&#x02022; Previous treatment with lenalidomide, if:<break/>&#x025cb; Refractory (i.e. stable disease (SD) or progressive disease (PD) on treatment or&#x02009;&#x02264;&#x02009;60&#x000a0;days after the end of treatment)<break/>&#x025cb; PD&#x02009;&#x02264;&#x02009;6&#x000a0;months after the end of treatment if patient had responded (i.e. &#x02265; MR)</td></tr><tr><td>&#x02022; Previous salvage HDCT/ASCT</td></tr><tr><td>&#x02022; Known hypersensitivity to thalidomide, lenalidomide or components of lenalidomide</td></tr><tr><td>&#x02022; Erythema nodosum as an exfoliative rash while on thalidomide</td></tr><tr><td>&#x02022; Exposure to any other experimental substance within 28&#x000a0;days prior to enrollment</td></tr><tr><td>&#x02022; Non-secretory MM (with normal free light chain ratio) that cannot be monitored by radiographic (e.g. MRI) examination</td></tr><tr><td>&#x02022; Systemic amyloidosis with organ involvement (with the exception of AL-amyloidosis of the skin and/or bone marrow)</td></tr><tr><td>&#x02022; Plasma cell leukemia</td></tr><tr><td>&#x02022; Previous allogeneic stem cell transplantation</td></tr><tr><td>&#x02022; Active, uncontrolled infectious disease</td></tr><tr><td>&#x02022; Known positivity for HIV, hepatitis B or C</td></tr><tr><td>&#x02022; Congestive heart failure (NYHA&#x02009;&#x02265;&#x02009;3)</td></tr><tr><td>&#x02022; Severe pulmonary, neurologic or psychiatric disease</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec11"><title>Trial procedures</title><p>An overview of the trial procedures and a checklist according to &#x0201c;Standard Protocol Items: Recommendations for Interventional Trials&#x0201d; (SPIRIT) guidelines are provided as Additional files <xref rid="MOESM1" ref-type="media">1</xref> and <xref rid="MOESM2" ref-type="media">2</xref>.</p><sec id="Sec12"><title>Screening</title><p>The following diagnostic investigations are performed at screening to determine patient eligibility for study participation and to assess disease status before study treatment: patient history and physical examination (including body weight, height, WHO performance score (PS), and concomitant diseases), laboratory investigations (complete blood count including absolute neutrophil count (ANC), electrolytes, renal parameters, hepatic parameters, thyroid stimulating hormone, C reactive protein, lactate dehydrogenase, albumin, total protein, pregnancy test if applicable, &#x003b2;-2 microglobulin, immunoglobulins, monoclonal protein and free light chains in serum, monoclonal protein in urine, immunofixation in serum and urine), bone marrow aspiration (cytology, interphase fluorescence in situ hybridization (iFISH) in CD138-purified plasma cells as described previously [<xref ref-type="bibr" rid="CR50">50</xref>]) radiographic imaging of the skeleton (low dose, whole body computed tomography (CT) or conventional X-ray imaging; appropriate imaging for disease quantification in case of non-secretory myeloma), electrocardiogram (ECG) and echocardiogram (exercise ECG if clinically indicated).</p></sec><sec id="Sec13"><title>Study visits</title><p>Study visits are scheduled at the respective study site after the initial 3 Rd cycles, after Rd cycle 5 (arm A) or 2&#x000a0;months after HDCT/ASCT (arm B), every three months thereafter and at the end of study participation. Diagnostic investigations performed at these visits for assessment of efficacy and safety, as well as patient eligibility to continue study treatment include: patient history and physical examination (including AEs, WHO PS, signs of thrombosis, assessment of soft tissue plasmacytomas), laboratory investigations (listed in <italic>Screening</italic>), bone marrow aspiration (only if CR or PD are suspected), radiographic imaging of the skeleton (if clinically indicated or at least once a year; more frequently for response assessment in non-secretory MM), and ECG and echocardiography (after the initial 3 Rd cycles, before HDCT and if clinically indicated). Additionally, complete blood counts including ANC are determined weekly during Rd cycles 1 and 2 and every 2 to 4&#x000a0;weeks thereafter for safety reasons. During HDCT/ASCT safety investigations are performed according to study site standards.</p></sec><sec id="Sec14"><title>Trial treatment</title><p>An overview of the treatment schedule is provided in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. Following randomization, all patients receive reinduction treatment consisting of 3 Rd cycles of 28&#x000a0;days each (oral lenalidomide 25&#x000a0;mg on days 1&#x02013;21, oral dexamethasone 40&#x000a0;mg on days 1, 8, 15, 22). Subsequently, all patients that do not have available stem cells from earlier harvesting (&#x02265;2*10<sup>6</sup> CD34+ cells*kg bw<sup>&#x02212;1</sup>) undergo peripheral blood stem cell mobilization and harvesting. Stem cell mobilization consists of cyclophosphamide (2&#x000a0;g*m<sup>&#x02212;2</sup> i.v. daily on days 1 and 2) and G-CSF (filgrastim 10&#x000a0;&#x003bc;g*kg<sup>&#x02212;1</sup>*d<sup>&#x02212;1</sup> or lenograstim 300&#x000a0;&#x003bc;g*m<sup>&#x02212;2</sup>*d<sup>&#x02212;1</sup> s.c. from day 5 until the end of apheresis); if unsuccessful, rescue mobilization with plerixafor is recommended. Determination of CD34+ cells in peripheral blood and leukapheresis are performed according to study site standard.<fig id="Fig1"><label>Fig. 1</label><caption><p>ReLApsE trial overview. <italic>Rd</italic>: 28&#x000a0;day&#x000a0;cycle of lenalidomide (25&#x000a0;mg p.o. daily on days 1-21) and low-dose dexamethoasone (40&#x000a0;mg p.o. daily on days 1, 8, 15, 22); <italic>cyclophosphamide</italic>: 2&#x000a0;g*m<sup>&#x02212;2</sup> i.v. daily on days 1 and 2; <italic>G-CSF</italic>: Filgrastim 10&#x000a0;&#x003bc;g*kg<sup>&#x02212;1</sup>*d<sup>&#x02212;1</sup> or lenograstim 300&#x000a0;&#x003bc;g*m<sup>&#x02212;2</sup>*d<sup>&#x02212;1</sup> s.c. daily from day 5 until the end of apheresis; <italic>HDCT</italic>: High dose chemotherapy (melphalan 100&#x000a0;mg*m<sup>&#x02212;2</sup> i.v. daily on days -3 and -2); <italic>ASCT</italic>: Autologous stem cell transplantation (&#x02265; 2*10<sup>6</sup> CD34+ cells*kg bw<sup>&#x02212;1</sup> on day 0); <italic>R-maintenance</italic>: Lenalidomide maintenance (10&#x000a0;mg p.o. daily)</p></caption><graphic xlink:href="12885_2016_2321_Fig1_HTML" id="MO1"/></fig></p><p>Patients in arm A then continue on consecutive Rd cycles (same dosages and intervals as reinduction treatment) until termination criteria are met.</p><p>Patients in arm B are examined for HDCT/ASCT eligibility (available stem cells; WHO PS&#x02009;&#x02264;&#x02009;2; absence of severe pulmonary, neurologic, or psychiatric disease; transaminases and bilirubin&#x02009;&#x02264;&#x02009;2,5 ULN; NYHA&#x02009;&#x02264;&#x02009;2) and - if eligible - undergo HDCT (melphalan 100&#x000a0;mg*m<sup>&#x02212;2</sup> i.v. daily on days -3 and -2) and autologous stem cell transplantation (&#x02265; 2*10<sup>6</sup> CD34+ cells*kg bw<sup>&#x02212;1</sup> i.v. on day 0) no later than 5&#x000a0;weeks after the end of reinduction treatment or stem cell harvesting. In the absence of ANC&#x02009;&#x0003c;&#x02009;1/nl, platelets&#x02009;&#x0003c;&#x02009;30/nl, active infections and PD, maintenance treatment with oral lenalidomide (10&#x000a0;mg daily) is initiated no later than 8&#x000a0;weeks after ASCT. Maintenance treatment is continued until termination criteria are met.</p><p>In the case of toxicities (e.g. grade 3/4 neutropenia, thrombocytopenia, non-hematologic toxicities) attributed to the study medication, doses of lenalidomide and/or dexamethasone are reduced according to predefined algorithms based on the prescribing information. All medication is adapted to renal function according to the prescribing information if necessary. Melphalan is reduced to a single dose of 100&#x000a0;mg*m<sup>&#x02212;2</sup> (day -3) if creatinine clearance is&#x02009;&#x02264;&#x02009;40&#x000a0;ml*min<sup>&#x02212;1</sup>.</p></sec><sec id="Sec15"><title>Supportive treatment</title><p>During cycle 1 of the reinduction treatment, all patients receive antibiotic prophylaxis with ciprofloxacin (500&#x000a0;mg twice daily). Antibiotic prophylaxis after cycle 1 is optional and based on clinical judgment. During reinduction treatment, all patients with platelets&#x02009;&#x02265;&#x02009;50/nl receive thrombosis prophylaxis with low molecular weight heparin (LMWH; enoxaparin 40&#x000a0;mg&#x000a0;s.c. daily). In arm A, thrombosis prophylaxis is switched to oral acetylsalicylic acid (100&#x000a0;mg daily) after Rd cycle 3 if no risk factors for thrombotic events are present; otherwise prophylaxis with LMWH is continued throughout the study treatment. During maintenance treatment in arm B thrombosis prophylaxis is not mandatory; however, it may be instituted based on clinical judgment.</p><p>Supportive treatment during stem cell mobilization/harvesting and HDCT/ASCT is performed according to study site standards.</p><p>Moreover, all patients are recommended to receive bisphosphonates (zoledronic acid 4&#x000a0;mg every 4&#x000a0;weeks i.v.). If VGPR is reached, duration of bisphosphonates should be limited to a total of 2&#x000a0;years. Due to the risk of bisphosphonate related osteonecrosis of the jaw, regular dental prophylaxis and temporary discontinuation of bisphosphonates as well as antibiotic prophylaxis in the context of invasive dental procedures are recommended.</p></sec><sec id="Sec16"><title>Concomitant medication and treatment</title><p>Antibiotic prophylaxis, thrombosis prophylaxis and bisphosphonate treatment are administered as described above. Furthermore, red blood cell and platelet transfusions, G-CSF administration, immunoglobulin substitution, treatment of myeloma- or treatment-associated complications, radiotherapy for the treatment of myeloma-induced pain, and glucocorticoids up to 10&#x000a0;mg of prednisone for the treatment of concomitant diseases are permitted. Substances with antineoplastic activity other than those administered according to the trial protocol are not allowed.</p></sec><sec id="Sec17"><title>Follow up</title><p>All patients are followed up after the end of study treatment on a regular basis, irrespective of the reason for discontinuation. During follow up, data on survival, toxicities, efficacy and subsequent myeloma-specific treatment including salvage HDCT/ASCT are collected.</p></sec></sec><sec id="Sec18"><title>Response assessment</title><p>Disease response is determined based on International Myeloma Working Group (IMWG) criteria [<xref ref-type="bibr" rid="CR51">51</xref>]. Minimal response (MR) as defined in the European Group for Bone and Marrow Transplantation (EBMT) criteria [<xref ref-type="bibr" rid="CR52">52</xref>] is assessed additionally. IMWG defined stringent CR is not assessed and IMWG defined relapse from CR is not considered for PFS calculation. Instead, the IMWG definition of PD is also used for PFS calculation of patients with CR.</p></sec><sec id="Sec19"><title>Discontinuation criteria</title><sec id="Sec20"><title>Discontinuation of trial participation of individual patients</title><p>In the case of any of the following events, trial participation of the patient in question is discontinued: patient wishes to discontinue study participation; continued study participation is disadvantageous for the patient according to the investigator; emergence of an exclusion criterion that precludes further participation in the trial according to the principal investigator; emergence of a (serious) AE that precludes further participation in the trial; pregnancy (for female patients); incorrect data due to protocol violations by the patient (e.g. non-compliance); confirmed PD or PD causing end organ damage (CRAB criteria [<xref ref-type="bibr" rid="CR53">53</xref>]), with the exception of asymptomatic PD after stem cell apheresis; trial completion according to the protocol.</p></sec><sec id="Sec21"><title>Closure of individual trial sites</title><p>The principal investigator may prematurely close individual trial sites in the case of inadequate recruiting or data quality provided by the trial site in question.</p></sec><sec id="Sec22"><title>Premature termination of the trial</title><p>The trial may be terminated prematurely by the principal investigator or the DSMB in the case of previously unknown risks or inadequate recruiting.</p></sec></sec><sec id="Sec23"><title>Statistical analysis</title><sec id="Sec24"><title>Power calculation</title><p>The calculated number of total trial patients required to prove clinically relevant inferiority of PFS in arm A vs. arm B at a power of 80&#x000a0;% is 282. This power calculation is based on the formula of <italic>Schoenfeld</italic> [<xref ref-type="bibr" rid="CR54">54</xref>] and the following assumptions: median PFS in arm A of 11&#x000a0;months (see prescribing information of lenalidomide); median PFS in arm B of 16.5&#x000a0;months (HR 0.67); Type 1 error of &#x003b1;&#x02009;=&#x02009;0.05 with an &#x003b1;-spending according to <italic>O&#x02019;Brien</italic> and <italic>Fleming</italic> [<xref ref-type="bibr" rid="CR55">55</xref>] of 0.0052 for the planned interim analysis and 0.048 for the final analysis; power (1-&#x003b2;) of 0.8; 1:1 randomization; constant HR; interim analysis (O&#x02019;Brien-Fleming Boundaries [<xref ref-type="bibr" rid="CR55">55</xref>]); 15&#x000a0;% loss to follow up/non-compliance.</p></sec><sec id="Sec25"><title>Study populations for analyses</title><p>Efficacy analyses are performed on an intent-to-treat (ITT) basis. The ITT population consists of all randomized patients. Patients with severe violation of inclusion/exclusion criteria are excluded. Patients are analyzed according to their randomization result. Safety analyses (toxicity, tolerability, medication) are performed on all patients that have received at least one administration of treatment according to the protocol. Patients are analyzed according to the received treatment.</p></sec><sec id="Sec26"><title>Statistical methods</title><p>The primary objective (PFS) is analyzed on a confirmatory basis at a two-sided significance level of &#x003b1;&#x02009;=&#x02009;0.048, which represents a significance level of &#x003b1;&#x02009;=&#x02009;0.05 with adjustment for an interim analysis. A two-sided, stratified logrank test is applied with study site and first-line HDCT/ASCT (yes or no) as variables for stratification. An unstratified logrank test and a multivariate proportional hazard Cox regression model are calculated on an exploratory basis. Secondary objectives are analyzed on a descriptive or exploratory basis. For hypothesis-generating tests explicit p values are given without adjustment of the significance level for multiple testing and therefore reflect Type 1 errors related to the individual comparison and not the overall experiment. OS is analyzed analogously to PFS. Distribution of PFS and OS is estimated according to the method of Kaplan-Meier. Known prognostic factors for PFS and OS such as &#x003b2;2M and the number of prior treatments are analyzed in a multivariate Cox model. For time to best response cumulative incidence rates are calculated with disease progression and death as competing risks. Multivariate analyses including the comparison of time to best response in both trial arms are performed using the proportional hazards model for competing risks according to <italic>Fine</italic> and <italic>Gray</italic> [<xref ref-type="bibr" rid="CR56">56</xref>]. The sole purpose of this analysis is the undistorted modeling of time to best response and not the estimation of competing risks. PFS and OS according to remission status before/after HDCT/ASCT are analyzed with landmark analyses (according to <italic>Anderson</italic> [<xref ref-type="bibr" rid="CR57">57</xref>]) and Cox regression model including remission status (CR/VGPR: yes vs. no) as time-dependent co-variable. Treatment response rates are evaluated with Fisher&#x02019;s exact test and Cochran/Armitage trend test. Demographic and clinical characteristics at enrollment are analyzed for homogeneity between both treatment groups. Toxicities in both treatment groups are compared in terms of type, frequency, CTC grading, and causality with Fisher&#x02019;s exact test and Cochran/Armitage trend test.</p></sec><sec id="Sec27"><title>Interim analysis</title><p>An interim analysis of preliminary efficacy (PFS) and safety (AEs) of the experimental trial arm (arm B) is performed after 96 PFS relevant events. The results are presented to the DSMB confidentially. The principal investigator only gains insight if the DSMB recommends to close the trial early or to alter the trial protocol. Additionally, the DSMB receives an annual report of the number of (serious) AEs and the number and severity of infections.</p></sec></sec></sec><sec id="Sec28"><title>Discussion</title><p>For RMM patients no universal therapeutic standard exists. Novel agents, especially lenalidomide in combination with dexamethasone are well evaluated [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>] and widely used in RMM patients. However, prospective data on salvage HDCT/ASCT are limited [<xref ref-type="bibr" rid="CR49">49</xref>] and no prospective, randomized trial evaluating the benefit of salvage HDCT/ASCT versus continued novel agent-based salvage treatment has been published. In the ReLApsE trial, HDCT/ASCT is integrated into and compared against the widely used Rd salvage regimen. Due to the fact that patients randomized into the continued Rd arm are recommended to receive salvage HDCT/ASCT for their next relapse, comparison of early versus late salvage HDCT/ASCT will be possible. Additionally, cytogenetic bone marrow analysis by iFISH is integrated into the diagnostic workup at trial screening which will allow for evaluation of the prognostic relevance of recurrent cytogenetic aberrations in the context of salvage HDCT/ASCT. The ReLApsE trial is therefore expected to generate clinically relevant information to help guide decision-making in the RMM setting.</p></sec></body><back><app-group><app id="App1"><sec id="Sec29"><title>Additional files</title><p><media position="anchor" xlink:href="12885_2016_2321_MOESM1_ESM.xls" id="MOESM1"><label>Additional file 1:</label><caption><p>SPIRIT schedule. (XLS 923&#x000a0;kb)</p></caption></media><media position="anchor" xlink:href="12885_2016_2321_MOESM2_ESM.doc" id="MOESM2"><label>Additional file 2:</label><caption><p>SPIRIT checklist. (DOC 121&#x000a0;kb)</p></caption></media></p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>AE</term><def><p>adverse event</p></def></def-item><def-item><term>ANC</term><def><p>absolute neutrophil count</p></def></def-item><def-item><term>ASCT</term><def><p>autologous stem cell transplantation</p></def></def-item><def-item><term>CR</term><def><p>complete response</p></def></def-item><def-item><term>CRAB</term><def><p>calcium elevation/renal failure/anemia/bone lesions</p></def></def-item><def-item><term>CT</term><def><p>computed tomography</p></def></def-item><def-item><term>CTCAE</term><def><p>Common Terminology Criteria of Adverse Events</p></def></def-item><def-item><term>DSMB</term><def><p>data safety monitoring board</p></def></def-item><def-item><term>EBMT</term><def><p>European Group for Bone and Marrow Transplantation</p></def></def-item><def-item><term>ECG</term><def><p>electrocardiogram</p></def></def-item><def-item><term>FPI</term><def><p>first patient in</p></def></def-item><def-item><term>HDCT</term><def><p>high dose chemotherapy</p></def></def-item><def-item><term>ICH-GCP</term><def><p>International Conference on Harmonization of good clinical practice</p></def></def-item><def-item><term>iFISH</term><def><p>interphase fluorescence in situ hybridization</p></def></def-item><def-item><term>IMiD</term><def><p>immunomodulatory drug</p></def></def-item><def-item><term>IMWG</term><def><p>International Myeloma Working Group</p></def></def-item><def-item><term>IRB</term><def><p>institutional review board</p></def></def-item><def-item><term>ITT</term><def><p>intent-to-treat</p></def></def-item><def-item><term>LMWH</term><def><p>low molecular weight heparin</p></def></def-item><def-item><term>LPI</term><def><p>last patient in</p></def></def-item><def-item><term>LPO</term><def><p>last patient out</p></def></def-item><def-item><term>MM</term><def><p>multiple myeloma</p></def></def-item><def-item><term>MR</term><def><p>minimal response</p></def></def-item><def-item><term>MRI</term><def><p>magnetic resonance imaging</p></def></def-item><def-item><term>ORR</term><def><p>overall response rate</p></def></def-item><def-item><term>OS</term><def><p>overall survival</p></def></def-item><def-item><term>PAD</term><def><p>bortezomib/doxorubicin/dexamethasone</p></def></def-item><def-item><term>PD</term><def><p>progressive disease</p></def></def-item><def-item><term>PFS</term><def><p>progression free survival</p></def></def-item><def-item><term>PI</term><def><p>proteasome inhibitor</p></def></def-item><def-item><term>PS</term><def><p>performance score</p></def></def-item><def-item><term>Rd</term><def><p>lenalidomide/dexamethasone</p></def></def-item><def-item><term>RMM</term><def><p>relapsed multiple myeloma</p></def></def-item><def-item><term>RR</term><def><p>response rate</p></def></def-item><def-item><term>SAE</term><def><p>serious adverse event</p></def></def-item><def-item><term>SUSAR</term><def><p>suspected unexpected serious adverse reaction</p></def></def-item><def-item><term>TRM</term><def><p>transplantation associated mortality</p></def></def-item><def-item><term>TTP</term><def><p>time to progression</p></def></def-item><def-item><term>VGPR</term><def><p>very good partial response</p></def></def-item><def-item><term>WHO</term><def><p>World health organization</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The GMMG ReLApsE trial (EudraCT 2009-013856-61, ISRCTN 16345835) is supported by grants from Celgene, Chugai and Amgen. Author-specific disclosures: RF: Celgene: consultancy, honoraria, research funding; Amgen: consultancy, honoraria. HG: Celgene: honoraria, advisory board, research funding; Chugai: honoraria, research funding; Amgen: advisory board. UG: Amgen: honoraria, advisory board, research funding. DH: Celgene: consultancy, research funding. JH: Celgene: honoraria; Amgen: consultancy. EKM: Celgene: travel grant. MSR: Celgene: honoraria, research funding, speakers&#x02018;bureau; Amgen: honoraria, research funding, speakers&#x02018;bureau. PR: Celgene: honoraria, travel grants. HJS: Celgene: honoraria, travel grants; Chugai: honoraria; Amgen: honoraria. KW: Celgene: honoraria, advisory board, research funding; Amgen: honoraria, advisory board. All other authors declare no potential conflict of interest.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>HG, TH, CK, SL and JS contributed to the development of the study concept and design. MAB, RF, MG, HG, UG, MH, JH, DH, AJ, SK, HWL, EKM, HM, MM, AN, RN, MSR, PR, HS, CS, MSH, IGHSW, KW and PW contribute to data acquisition. HG, TH, CK and JS contribute to data analysis. MAB, RF, MG, HG, UG, MH, JH, ADH, DH, AJ, SK, HWL, EKM, HM, MM, AN, RN, MSR, PR, HS, CS, JS, MSH, IGHSW, KW and PW contributed to the writing and revision of the manuscript. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank the investigators, the study nurses and all members of the study teams at the participating GMMG trial sites, the myeloma research laboratory team, the FISH laboratory team and the central laboratory at the University Hospital Heidelberg, the coordination centers for clinical trials (KKS) in Heidelberg and Leipzig, the pharmacies at the trial sites and, most importantly, the participating patients and their families. This trial is supported by the Dietmar Hopp Stiftung and grants from Celgene, Chugai and Amgen.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palumbo</surname><given-names>A</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name></person-group><article-title>Multiple myeloma</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><fpage>1046</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1011442</pub-id><pub-id pub-id-type="pmid">21410373</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavo</surname><given-names>M</given-names></name><name><surname>Rajkumar</surname><given-names>SV</given-names></name><name><surname>Palumbo</surname><given-names>A</given-names></name><name><surname>Moreau</surname><given-names>P</given-names></name><name><surname>Orlowski</surname><given-names>R</given-names></name><name><surname>Blade</surname><given-names>J</given-names></name><name><surname>Sezer</surname><given-names>O</given-names></name><name><surname>Ludwig</surname><given-names>H</given-names></name><name><surname>Dimopoulos</surname><given-names>MA</given-names></name><name><surname>Attal</surname><given-names>M</given-names></name><name><surname>Sonneveld</surname><given-names>P</given-names></name><name><surname>Boccadoro</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Bensinger</surname><given-names>W</given-names></name><name><surname>Johnsen</surname><given-names>HE</given-names></name><name><surname>Kroeger</surname><given-names>N</given-names></name><name><surname>Gahrton</surname><given-names>G</given-names></name><name><surname>Bergsagel</surname><given-names>PL</given-names></name><name><surname>Vesole</surname><given-names>DH</given-names></name><name><surname>Einsele</surname><given-names>H</given-names></name><name><surname>Jagannath</surname><given-names>S</given-names></name><name><surname>Niesvizky</surname><given-names>R</given-names></name><name><surname>Durie</surname><given-names>BGM</given-names></name><name><surname>San Miguel</surname><given-names>J</given-names></name><name><surname>Lonial</surname><given-names>S</given-names></name></person-group><article-title>International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation</article-title><source>Blood</source><year>2011</year><volume>117</volume><fpage>6063</fpage><lpage>6073</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-02-297325</pub-id><pub-id pub-id-type="pmid">21447828</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engelhardt</surname><given-names>M</given-names></name><name><surname>Terpos</surname><given-names>E</given-names></name><name><surname>Kleber</surname><given-names>M</given-names></name><name><surname>Gay</surname><given-names>F</given-names></name><name><surname>Wasch</surname><given-names>R</given-names></name><name><surname>Morgan</surname><given-names>G</given-names></name><name><surname>Cavo</surname><given-names>M</given-names></name><name><surname>van de Donk</surname><given-names>N</given-names></name><name><surname>Beilhack</surname><given-names>A</given-names></name><name><surname>Bruno</surname><given-names>B</given-names></name><name><surname>Johnsen</surname><given-names>HE</given-names></name><name><surname>Hajek</surname><given-names>R</given-names></name><name><surname>Driessen</surname><given-names>C</given-names></name><name><surname>Ludwig</surname><given-names>H</given-names></name><name><surname>Beksac</surname><given-names>M</given-names></name><name><surname>Boccadoro</surname><given-names>M</given-names></name><name><surname>Straka</surname><given-names>C</given-names></name><name><surname>Brighen</surname><given-names>S</given-names></name><name><surname>Gramatzki</surname><given-names>M</given-names></name><name><surname>Larocca</surname><given-names>A</given-names></name><name><surname>Lokhorst</surname><given-names>H</given-names></name><name><surname>Magarotto</surname><given-names>V</given-names></name><name><surname>Morabito</surname><given-names>F</given-names></name><name><surname>Dimopoulos</surname><given-names>MA</given-names></name><name><surname>Einsele</surname><given-names>H</given-names></name><name><surname>Sonneveld</surname><given-names>P</given-names></name><name><surname>Palumbo</surname><given-names>A</given-names></name></person-group><article-title>European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma</article-title><source>Haematologica</source><year>2014</year><volume>99</volume><fpage>232</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.3324/haematol.2013.099358</pub-id><pub-id pub-id-type="pmid">24497560</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimopoulos</surname><given-names>MA</given-names></name><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Moreau</surname><given-names>P</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>Current treatment landscape for relapsed and/or refractory multiple myeloma</article-title><source>Nat Rev Clin Oncol</source><year>2014</year><volume>12</volume><fpage>42</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2014.200</pub-id><pub-id pub-id-type="pmid">25421279</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singhal</surname><given-names>S</given-names></name><name><surname>Mehta</surname><given-names>J</given-names></name><name><surname>Desikan</surname><given-names>R</given-names></name><name><surname>Ayers</surname><given-names>D</given-names></name><name><surname>Roberson</surname><given-names>P</given-names></name><name><surname>Eddlemon</surname><given-names>P</given-names></name><name><surname>Munshi</surname><given-names>N</given-names></name><name><surname>Anaissie</surname><given-names>E</given-names></name><name><surname>Wilson</surname><given-names>C</given-names></name><name><surname>Dhodapkar</surname><given-names>M</given-names></name><name><surname>Zeddis</surname><given-names>J</given-names></name><name><surname>Barlogie</surname><given-names>B</given-names></name></person-group><article-title>Antitumor activity of thalidomide in refractory multiple myeloma</article-title><source>N Engl J Med</source><year>1999</year><volume>341</volume><fpage>1565</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1056/NEJM199911183412102</pub-id><pub-id pub-id-type="pmid">10564685</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palumbo</surname><given-names>A</given-names></name><name><surname>Falco</surname><given-names>P</given-names></name><name><surname>Ambrosini</surname><given-names>MT</given-names></name><name><surname>Petrucci</surname><given-names>MT</given-names></name><name><surname>Musto</surname><given-names>P</given-names></name><name><surname>Caravita</surname><given-names>T</given-names></name><name><surname>Pregno</surname><given-names>P</given-names></name><name><surname>Bertola</surname><given-names>A</given-names></name><name><surname>Cavallo</surname><given-names>F</given-names></name><name><surname>Ciccone</surname><given-names>G</given-names></name><name><surname>Boccadoro</surname><given-names>M</given-names></name></person-group><article-title>Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant</article-title><source>Eur J Haematol</source><year>2005</year><volume>75</volume><fpage>391</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0609.2005.00533.x</pub-id><pub-id pub-id-type="pmid">16191088</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Sonneveld</surname><given-names>P</given-names></name><name><surname>Schuster</surname><given-names>MW</given-names></name><name><surname>Irwin</surname><given-names>D</given-names></name><name><surname>Stadtmauer</surname><given-names>EA</given-names></name><name><surname>Facon</surname><given-names>T</given-names></name><name><surname>Harousseau</surname><given-names>J-L</given-names></name><name><surname>Ben-Yehuda</surname><given-names>D</given-names></name><name><surname>Lonial</surname><given-names>S</given-names></name><name><surname>Goldschmidt</surname><given-names>H</given-names></name><name><surname>Reece</surname><given-names>D</given-names></name><name><surname>San-Miguel</surname><given-names>JF</given-names></name><name><surname>Blad&#x000e9;</surname><given-names>J</given-names></name><name><surname>Boccadoro</surname><given-names>M</given-names></name><name><surname>Cavenagh</surname><given-names>J</given-names></name><name><surname>Dalton</surname><given-names>WS</given-names></name><name><surname>Boral</surname><given-names>AL</given-names></name><name><surname>Esseltine</surname><given-names>DL</given-names></name><name><surname>Porter</surname><given-names>JB</given-names></name><name><surname>Schenkein</surname><given-names>D</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>Bortezomib or high-dose dexamethasone for relapsed multiple myeloma</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>2487</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa043445</pub-id><pub-id pub-id-type="pmid">15958804</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>DM</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Niesvizky</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Belch</surname><given-names>A</given-names></name><name><surname>Stadtmauer</surname><given-names>EA</given-names></name><name><surname>Siegel</surname><given-names>D</given-names></name><name><surname>Borrello</surname><given-names>I</given-names></name><name><surname>Rajkumar</surname><given-names>SV</given-names></name><name><surname>Chanan-Khan</surname><given-names>AA</given-names></name><name><surname>Lonial</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Patin</surname><given-names>J</given-names></name><name><surname>Olesnyckyj</surname><given-names>M</given-names></name><name><surname>Zeldis</surname><given-names>JB</given-names></name><name><surname>Knight</surname><given-names>RD</given-names></name></person-group><article-title>Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><fpage>2133</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa070596</pub-id><pub-id pub-id-type="pmid">18032763</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimopoulos</surname><given-names>M</given-names></name><name><surname>Spencer</surname><given-names>A</given-names></name><name><surname>Attal</surname><given-names>M</given-names></name><name><surname>Prince</surname><given-names>HM</given-names></name><name><surname>Harousseau</surname><given-names>J-L</given-names></name><name><surname>Dmoszynska</surname><given-names>A</given-names></name><name><surname>San Miguel</surname><given-names>J</given-names></name><name><surname>Hellmann</surname><given-names>A</given-names></name><name><surname>Facon</surname><given-names>T</given-names></name><name><surname>Fo&#x000e0;</surname><given-names>R</given-names></name><name><surname>Corso</surname><given-names>A</given-names></name><name><surname>Masliak</surname><given-names>Z</given-names></name><name><surname>Olesnyckyj</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Patin</surname><given-names>J</given-names></name><name><surname>Zeldis</surname><given-names>JB</given-names></name><name><surname>Knight</surname><given-names>RD</given-names></name></person-group><article-title>Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><fpage>2123</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa070594</pub-id><pub-id pub-id-type="pmid">18032762</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>San Miguel</surname><given-names>J</given-names></name><name><surname>Weisel</surname><given-names>K</given-names></name><name><surname>Moreau</surname><given-names>P</given-names></name><name><surname>Lacy</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>K</given-names></name><name><surname>Delforge</surname><given-names>M</given-names></name><name><surname>Karlin</surname><given-names>L</given-names></name><name><surname>Goldschmidt</surname><given-names>H</given-names></name><name><surname>Banos</surname><given-names>A</given-names></name><name><surname>Oriol</surname><given-names>A</given-names></name><name><surname>Alegre</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Cavo</surname><given-names>M</given-names></name><name><surname>Garderet</surname><given-names>L</given-names></name><name><surname>Ivanova</surname><given-names>V</given-names></name><name><surname>Martinez-Lopez</surname><given-names>J</given-names></name><name><surname>Belch</surname><given-names>A</given-names></name><name><surname>Palumbo</surname><given-names>A</given-names></name><name><surname>Schey</surname><given-names>S</given-names></name><name><surname>Sonneveld</surname><given-names>P</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Sternas</surname><given-names>L</given-names></name><name><surname>Jacques</surname><given-names>C</given-names></name><name><surname>Zaki</surname><given-names>M</given-names></name><name><surname>Dimopoulos</surname><given-names>M</given-names></name></person-group><article-title>Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial</article-title><source>Lancet Oncol</source><year>2013</year><volume>14</volume><fpage>1055</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70380-2</pub-id><pub-id pub-id-type="pmid">24007748</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>AK</given-names></name><name><surname>Rajkumar</surname><given-names>SV</given-names></name><name><surname>Dimopoulos</surname><given-names>MA</given-names></name><name><surname>Masszi</surname><given-names>T</given-names></name><name><surname>&#x00160;pi&#x0010d;ka</surname><given-names>I</given-names></name><name><surname>Oriol</surname><given-names>A</given-names></name><name><surname>H&#x000e1;jek</surname><given-names>R</given-names></name><name><surname>Rosi&#x000f1;ol</surname><given-names>L</given-names></name><name><surname>Siegel</surname><given-names>DS</given-names></name><name><surname>Mihaylov</surname><given-names>GG</given-names></name><name><surname>Goranova-Marinova</surname><given-names>V</given-names></name><name><surname>Rajnics</surname><given-names>P</given-names></name><name><surname>Suvorov</surname><given-names>A</given-names></name><name><surname>Niesvizky</surname><given-names>R</given-names></name><name><surname>Jakubowiak</surname><given-names>AJ</given-names></name><name><surname>San-Miguel</surname><given-names>JF</given-names></name><name><surname>Ludwig</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Maisnar</surname><given-names>V</given-names></name><name><surname>Minarik</surname><given-names>J</given-names></name><name><surname>Bensinger</surname><given-names>WI</given-names></name><name><surname>Mateos</surname><given-names>M-V</given-names></name><name><surname>Ben-Yehuda</surname><given-names>D</given-names></name><name><surname>Kukreti</surname><given-names>V</given-names></name><name><surname>Zojwalla</surname><given-names>N</given-names></name><name><surname>Tonda</surname><given-names>ME</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Xing</surname><given-names>B</given-names></name><name><surname>Moreau</surname><given-names>P</given-names></name><name><surname>Palumbo</surname><given-names>A</given-names></name></person-group><article-title>Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma</article-title><source>N Engl J Med</source><year>2014</year><volume>372</volume><fpage>141206080130007</fpage></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marriott</surname><given-names>JB</given-names></name><name><surname>Dredge</surname><given-names>K</given-names></name><name><surname>Dalgleish</surname><given-names>AG</given-names></name></person-group><article-title>Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents</article-title><source>Curr Drug Targets Immune Endocr Metabol Disord</source><year>2003</year><volume>3</volume><fpage>181</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.2174/1568008033340207</pub-id><pub-id pub-id-type="pmid">12871024</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotla</surname><given-names>V</given-names></name><name><surname>Goel</surname><given-names>S</given-names></name><name><surname>Nischal</surname><given-names>S</given-names></name><name><surname>Heuck</surname><given-names>C</given-names></name><name><surname>Vivek</surname><given-names>K</given-names></name><name><surname>Das</surname><given-names>B</given-names></name><name><surname>Verma</surname><given-names>A</given-names></name></person-group><article-title>Mechanism of action of lenalidomide in hematological malignancies</article-title><source>J Hematol Oncol</source><year>2009</year><volume>2</volume><fpage>36</fpage><pub-id pub-id-type="doi">10.1186/1756-8722-2-36</pub-id><pub-id pub-id-type="pmid">19674465</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quach</surname><given-names>H</given-names></name><name><surname>Ritchie</surname><given-names>D</given-names></name><name><surname>Stewart</surname><given-names>AK</given-names></name><name><surname>Neeson</surname><given-names>P</given-names></name><name><surname>Harrison</surname><given-names>S</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Prince</surname><given-names>HM</given-names></name></person-group><article-title>Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma</article-title><source>Leukemia</source><year>2010</year><volume>24</volume><fpage>22</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1038/leu.2009.236</pub-id><pub-id pub-id-type="pmid">19907437</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Podar</surname><given-names>K</given-names></name><name><surname>Schlossman</surname><given-names>RL</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>Novel therapies targeting the myeloma cell and its bone marrow microenvironment</article-title><source>Semin Oncol</source><year>2001</year><volume>28</volume><fpage>607</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/S0093-7754(01)90033-8</pub-id><pub-id pub-id-type="pmid">11740818</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dredge</surname><given-names>K</given-names></name><name><surname>Marriott</surname><given-names>JB</given-names></name><name><surname>Macdonald</surname><given-names>CD</given-names></name><name><surname>Man</surname><given-names>H-W</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Muller</surname><given-names>GW</given-names></name><name><surname>Stirling</surname><given-names>D</given-names></name><name><surname>Dalgleish</surname><given-names>AG</given-names></name></person-group><article-title>Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects</article-title><source>Br J Cancer</source><year>2002</year><volume>87</volume><fpage>1166</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6600607</pub-id><pub-id pub-id-type="pmid">12402158</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dredge</surname><given-names>K</given-names></name><name><surname>Horsfall</surname><given-names>R</given-names></name><name><surname>Robinson</surname><given-names>SP</given-names></name><name><surname>Zhang</surname><given-names>L-H</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Shirley</surname><given-names>MA</given-names></name><name><surname>Muller</surname><given-names>G</given-names></name><name><surname>Schafer</surname><given-names>P</given-names></name><name><surname>Stirling</surname><given-names>D</given-names></name><name><surname>Dalgleish</surname><given-names>AG</given-names></name><name><surname>Bartlett</surname><given-names>JB</given-names></name></person-group><article-title>Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro</article-title><source>Microvasc Res</source><year>2005</year><volume>69</volume><fpage>56</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.mvr.2005.01.002</pub-id><pub-id pub-id-type="pmid">15797261</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corral</surname><given-names>LG</given-names></name><name><surname>Haslett</surname><given-names>PA</given-names></name><name><surname>Muller</surname><given-names>GW</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Wong</surname><given-names>LM</given-names></name><name><surname>Ocampo</surname><given-names>CJ</given-names></name><name><surname>Patterson</surname><given-names>RT</given-names></name><name><surname>Stirling</surname><given-names>DI</given-names></name><name><surname>Kaplan</surname><given-names>G</given-names></name></person-group><article-title>Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha</article-title><source>J Immunol</source><year>1999</year><volume>163</volume><fpage>380</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10384139</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>FE</given-names></name><name><surname>Raje</surname><given-names>N</given-names></name><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Lentzsch</surname><given-names>S</given-names></name><name><surname>Young</surname><given-names>G</given-names></name><name><surname>Tai</surname><given-names>YT</given-names></name><name><surname>Lin</surname><given-names>B</given-names></name><name><surname>Podar</surname><given-names>K</given-names></name><name><surname>Gupta</surname><given-names>D</given-names></name><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Treon</surname><given-names>SP</given-names></name><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Schlossman</surname><given-names>RL</given-names></name><name><surname>Morgan</surname><given-names>GJ</given-names></name><name><surname>Muller</surname><given-names>GW</given-names></name><name><surname>Stirling</surname><given-names>DI</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma</article-title><source>Blood</source><year>2001</year><volume>98</volume><fpage>210</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1182/blood.V98.1.210</pub-id><pub-id pub-id-type="pmid">11418482</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Ando</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Ogura</surname><given-names>T</given-names></name><name><surname>Hotta</surname><given-names>K</given-names></name><name><surname>Imamura</surname><given-names>Y</given-names></name><name><surname>Yamaguchi</surname><given-names>Y</given-names></name><name><surname>Handa</surname><given-names>H</given-names></name></person-group><article-title>Identification of a primary target of thalidomide teratogenicity</article-title><source>Science</source><year>2010</year><volume>327</volume><fpage>1345</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1126/science.1177319</pub-id><pub-id pub-id-type="pmid">20223979</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>YX</given-names></name><name><surname>Braggio</surname><given-names>E</given-names></name><name><surname>Shi</surname><given-names>C-X</given-names></name><name><surname>Bruins</surname><given-names>LA</given-names></name><name><surname>Schmidt</surname><given-names>JE</given-names></name><name><surname>Van Wier</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>X-B</given-names></name><name><surname>Bjorklund</surname><given-names>CC</given-names></name><name><surname>Fonseca</surname><given-names>R</given-names></name><name><surname>Bergsagel</surname><given-names>PL</given-names></name><name><surname>Orlowski</surname><given-names>RZ</given-names></name><name><surname>Stewart</surname><given-names>AK</given-names></name></person-group><article-title>Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide</article-title><source>Blood</source><year>2011</year><volume>118</volume><fpage>4771</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-05-356063</pub-id><pub-id pub-id-type="pmid">21860026</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heintel</surname><given-names>D</given-names></name><name><surname>Rocci</surname><given-names>A</given-names></name><name><surname>Ludwig</surname><given-names>H</given-names></name><name><surname>Bolomsky</surname><given-names>A</given-names></name><name><surname>Caltagirone</surname><given-names>S</given-names></name><name><surname>Schreder</surname><given-names>M</given-names></name><name><surname>Pfeifer</surname><given-names>S</given-names></name><name><surname>Gisslinger</surname><given-names>H</given-names></name><name><surname>Zojer</surname><given-names>N</given-names></name><name><surname>J&#x000e4;ger</surname><given-names>U</given-names></name><name><surname>Palumbo</surname><given-names>A</given-names></name></person-group><article-title>High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone</article-title><source>Br J Haematol</source><year>2013</year><volume>161</volume><fpage>695</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1111/bjh.12338</pub-id><pub-id pub-id-type="pmid">23565715</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimopoulos</surname><given-names>MA</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Spencer</surname><given-names>A</given-names></name><name><surname>Niesvizky</surname><given-names>R</given-names></name><name><surname>Attal</surname><given-names>M</given-names></name><name><surname>Stadtmauer</surname><given-names>EA</given-names></name><name><surname>Petrucci</surname><given-names>MT</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Olesnyckyj</surname><given-names>M</given-names></name><name><surname>Zeldis</surname><given-names>JB</given-names></name><name><surname>Knight</surname><given-names>RD</given-names></name><name><surname>Weber</surname><given-names>DM</given-names></name></person-group><article-title>Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma</article-title><source>Leukemia</source><year>2009</year><volume>23</volume><fpage>2147</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1038/leu.2009.147</pub-id><pub-id pub-id-type="pmid">19626046</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajkumar</surname><given-names>SV</given-names></name><name><surname>Jacobus</surname><given-names>S</given-names></name><name><surname>Callander</surname><given-names>NS</given-names></name><name><surname>Fonseca</surname><given-names>R</given-names></name><name><surname>Vesole</surname><given-names>DH</given-names></name><name><surname>Williams</surname><given-names>ME</given-names></name><name><surname>Abonour</surname><given-names>R</given-names></name><name><surname>Siegel</surname><given-names>DS</given-names></name><name><surname>Katz</surname><given-names>M</given-names></name><name><surname>Greipp</surname><given-names>PR</given-names></name></person-group><article-title>Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial</article-title><source>Lancet Oncol</source><year>2010</year><volume>11</volume><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(09)70284-0</pub-id><pub-id pub-id-type="pmid">19853510</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miguel</surname><given-names>J</given-names></name><name><surname>Dimopoulos</surname><given-names>M</given-names></name><name><surname>Weber</surname><given-names>D</given-names></name><name><surname>Olesnyckyi</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Zeldis</surname><given-names>J</given-names></name></person-group><article-title>Dexamethasone dose adjustmenst seem to result in better efficacy and improved tolerability in patients with relapsed/refractory multiple myeloma who are treated with lenalidomide/dexamethasone (MM009/010 Sub-Analysis)</article-title><source>ASH Annu Meet Abstr</source><year>2007</year><volume>110</volume><fpage>2712</fpage></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attal</surname><given-names>M</given-names></name><name><surname>Lauwers-Cances</surname><given-names>V</given-names></name><name><surname>Marit</surname><given-names>G</given-names></name><name><surname>Caillot</surname><given-names>D</given-names></name><name><surname>Moreau</surname><given-names>P</given-names></name><name><surname>Facon</surname><given-names>T</given-names></name><name><surname>Stoppa</surname><given-names>AM</given-names></name><name><surname>Hulin</surname><given-names>C</given-names></name><name><surname>Benboubker</surname><given-names>L</given-names></name><name><surname>Garderet</surname><given-names>L</given-names></name><name><surname>Decaux</surname><given-names>O</given-names></name><name><surname>Leyvraz</surname><given-names>S</given-names></name><name><surname>Vekemans</surname><given-names>M-C</given-names></name><name><surname>Voillat</surname><given-names>L</given-names></name><name><surname>Michallet</surname><given-names>M</given-names></name><name><surname>Pegourie</surname><given-names>B</given-names></name><name><surname>Dumontet</surname><given-names>C</given-names></name><name><surname>Roussel</surname><given-names>M</given-names></name><name><surname>Leleu</surname><given-names>X</given-names></name><name><surname>Mathiot</surname><given-names>C</given-names></name><name><surname>Payen</surname><given-names>C</given-names></name><name><surname>Avet-Loiseau</surname><given-names>H</given-names></name><name><surname>Harousseau</surname><given-names>J-L</given-names></name></person-group><article-title>Lenalidomide maintenance after stem-cell transplantation for multiple myeloma</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><fpage>1782</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1114138</pub-id><pub-id pub-id-type="pmid">22571202</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>PL</given-names></name><name><surname>Owzar</surname><given-names>K</given-names></name><name><surname>Hofmeister</surname><given-names>CC</given-names></name><name><surname>Hurd</surname><given-names>DD</given-names></name><name><surname>Hassoun</surname><given-names>H</given-names></name><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Giralt</surname><given-names>S</given-names></name><name><surname>Stadtmauer</surname><given-names>EA</given-names></name><name><surname>Weisdorf</surname><given-names>DJ</given-names></name><name><surname>Vij</surname><given-names>R</given-names></name><name><surname>Moreb</surname><given-names>JS</given-names></name><name><surname>Callander</surname><given-names>NS</given-names></name><name><surname>Van Besien</surname><given-names>K</given-names></name><name><surname>Gentile</surname><given-names>T</given-names></name><name><surname>Isola</surname><given-names>L</given-names></name><name><surname>Maziarz</surname><given-names>RT</given-names></name><name><surname>Gabriel</surname><given-names>DA</given-names></name><name><surname>Bashey</surname><given-names>A</given-names></name><name><surname>Landau</surname><given-names>H</given-names></name><name><surname>Martin</surname><given-names>T</given-names></name><name><surname>Qazilbash</surname><given-names>MH</given-names></name><name><surname>Levitan</surname><given-names>D</given-names></name><name><surname>McClune</surname><given-names>B</given-names></name><name><surname>Schlossman</surname><given-names>R</given-names></name><name><surname>Hars</surname><given-names>V</given-names></name><name><surname>Postiglione</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Bennett</surname><given-names>E</given-names></name><name><surname>Barry</surname><given-names>S</given-names></name><name><surname>Bressler</surname><given-names>L</given-names></name><etal/></person-group><article-title>Lenalidomide after stem-cell transplantation for multiple myeloma</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><fpage>1770</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1114083</pub-id><pub-id pub-id-type="pmid">22571201</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palumbo</surname><given-names>A</given-names></name><name><surname>Cavallo</surname><given-names>F</given-names></name><name><surname>Gay</surname><given-names>F</given-names></name><name><surname>Di Raimondo</surname><given-names>F</given-names></name><name><surname>Ben Yehuda</surname><given-names>D</given-names></name><name><surname>Petrucci</surname><given-names>MT</given-names></name><name><surname>Pezzatti</surname><given-names>S</given-names></name><name><surname>Caravita</surname><given-names>T</given-names></name><name><surname>Cerrato</surname><given-names>C</given-names></name><name><surname>Ribakovsky</surname><given-names>E</given-names></name><name><surname>Genuardi</surname><given-names>M</given-names></name><name><surname>Cafro</surname><given-names>A</given-names></name><name><surname>Marcatti</surname><given-names>M</given-names></name><name><surname>Catalano</surname><given-names>L</given-names></name><name><surname>Offidani</surname><given-names>M</given-names></name><name><surname>Carella</surname><given-names>AM</given-names></name><name><surname>Zamagni</surname><given-names>E</given-names></name><name><surname>Patriarca</surname><given-names>F</given-names></name><name><surname>Musto</surname><given-names>P</given-names></name><name><surname>Evangelista</surname><given-names>A</given-names></name><name><surname>Ciccone</surname><given-names>G</given-names></name><name><surname>Omed&#x000e9;</surname><given-names>P</given-names></name><name><surname>Crippa</surname><given-names>C</given-names></name><name><surname>Corradini</surname><given-names>P</given-names></name><name><surname>Nagler</surname><given-names>A</given-names></name><name><surname>Boccadoro</surname><given-names>M</given-names></name><name><surname>Cavo</surname><given-names>M</given-names></name></person-group><article-title>Autologous Transplantation and Maintenance Therapy in Multiple Myeloma</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><fpage>895</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1402888</pub-id><pub-id pub-id-type="pmid">25184862</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palumbo</surname><given-names>A</given-names></name><name><surname>Hajek</surname><given-names>R</given-names></name><name><surname>Delforge</surname><given-names>M</given-names></name><name><surname>Kropff</surname><given-names>M</given-names></name><name><surname>Petrucci</surname><given-names>MT</given-names></name><name><surname>Catalano</surname><given-names>J</given-names></name><name><surname>Gisslinger</surname><given-names>H</given-names></name><name><surname>Wiktor-J&#x00119;drzejczak</surname><given-names>W</given-names></name><name><surname>Zodelava</surname><given-names>M</given-names></name><name><surname>Weisel</surname><given-names>K</given-names></name><name><surname>Cascavilla</surname><given-names>N</given-names></name><name><surname>Iosava</surname><given-names>G</given-names></name><name><surname>Cavo</surname><given-names>M</given-names></name><name><surname>Kloczko</surname><given-names>J</given-names></name><name><surname>Blad&#x000e9;</surname><given-names>J</given-names></name><name><surname>Beksac</surname><given-names>M</given-names></name><name><surname>Spicka</surname><given-names>I</given-names></name><name><surname>Plesner</surname><given-names>T</given-names></name><name><surname>Radke</surname><given-names>J</given-names></name><name><surname>Langer</surname><given-names>C</given-names></name><name><surname>Ben Yehuda</surname><given-names>D</given-names></name><name><surname>Corso</surname><given-names>A</given-names></name><name><surname>Herbein</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Mei</surname><given-names>J</given-names></name><name><surname>Jacques</surname><given-names>C</given-names></name><name><surname>Dimopoulos</surname><given-names>MA</given-names></name></person-group><article-title>Continuous lenalidomide treatment for newly diagnosed multiple myeloma</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><fpage>1759</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1112704</pub-id><pub-id pub-id-type="pmid">22571200</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palumbo</surname><given-names>A</given-names></name><name><surname>Bringhen</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>SK</given-names></name><name><surname>Lupparelli</surname><given-names>G</given-names></name><name><surname>Usmani</surname><given-names>S</given-names></name><name><surname>Waage</surname><given-names>A</given-names></name><name><surname>Larocca</surname><given-names>A</given-names></name><name><surname>van der Holt</surname><given-names>B</given-names></name><name><surname>Musto</surname><given-names>P</given-names></name><name><surname>Offidani</surname><given-names>M</given-names></name><name><surname>Petrucci</surname><given-names>MT</given-names></name><name><surname>Evangelista</surname><given-names>A</given-names></name><name><surname>Zweegman</surname><given-names>S</given-names></name><name><surname>Nooka</surname><given-names>AK</given-names></name><name><surname>Spencer</surname><given-names>A</given-names></name><name><surname>Dimopoulos</surname><given-names>MA</given-names></name><name><surname>Hajek</surname><given-names>R</given-names></name><name><surname>Cavo</surname><given-names>M</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Lonial</surname><given-names>S</given-names></name><name><surname>Ciccone</surname><given-names>G</given-names></name><name><surname>Boccadoro</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name><name><surname>Barlogie</surname><given-names>B</given-names></name><name><surname>Sonneveld</surname><given-names>P</given-names></name><name><surname>McCarthy</surname><given-names>PL</given-names></name></person-group><article-title>Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><fpage>333</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70609-0</pub-id><pub-id pub-id-type="pmid">24525202</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludwig</surname><given-names>H</given-names></name><name><surname>Miguel</surname><given-names>JS</given-names></name><name><surname>Dimopoulos</surname><given-names>MA</given-names></name><name><surname>Palumbo</surname><given-names>A</given-names></name><name><surname>Garcia Sanz</surname><given-names>R</given-names></name><name><surname>Powles</surname><given-names>R</given-names></name><name><surname>Lentzsch</surname><given-names>S</given-names></name><name><surname>Ming Chen</surname><given-names>W</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Jurczyszyn</surname><given-names>A</given-names></name><name><surname>Romeril</surname><given-names>K</given-names></name><name><surname>Hajek</surname><given-names>R</given-names></name><name><surname>Terpos</surname><given-names>E</given-names></name><name><surname>Shimizu</surname><given-names>K</given-names></name><name><surname>Joshua</surname><given-names>D</given-names></name><name><surname>Hungria</surname><given-names>V</given-names></name><name><surname>Rodriguez Morales</surname><given-names>A</given-names></name><name><surname>Ben-Yehuda</surname><given-names>D</given-names></name><name><surname>Sondergeld</surname><given-names>P</given-names></name><name><surname>Zamagni</surname><given-names>E</given-names></name><name><surname>Durie</surname><given-names>B</given-names></name></person-group><article-title>International Myeloma Working Group recommendations for global myeloma care</article-title><source>Leukemia</source><year>2014</year><volume>28</volume><fpage>981</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1038/leu.2013.293</pub-id><pub-id pub-id-type="pmid">24177258</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tricot</surname><given-names>G</given-names></name><name><surname>Jagannath</surname><given-names>S</given-names></name><name><surname>Vesole</surname><given-names>DH</given-names></name><name><surname>Crowley</surname><given-names>J</given-names></name><name><surname>Barlogie</surname><given-names>B</given-names></name></person-group><article-title>Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy</article-title><source>Bone Marrow Transplant</source><year>1995</year><volume>16</volume><fpage>7</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">7581132</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vesole</surname><given-names>DH</given-names></name><name><surname>Crowley</surname><given-names>JJ</given-names></name><name><surname>Catchatourian</surname><given-names>R</given-names></name><name><surname>Stiff</surname><given-names>PJ</given-names></name><name><surname>Johnson</surname><given-names>DB</given-names></name><name><surname>Cromer</surname><given-names>J</given-names></name><name><surname>Salmon</surname><given-names>SE</given-names></name><name><surname>Barlogie</surname><given-names>B</given-names></name></person-group><article-title>High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>2173</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10561273</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajkumar</surname><given-names>SV</given-names></name><name><surname>Fonseca</surname><given-names>R</given-names></name><name><surname>Lacy</surname><given-names>MQ</given-names></name><name><surname>Witzig</surname><given-names>TE</given-names></name><name><surname>Lust</surname><given-names>JA</given-names></name><name><surname>Greipp</surname><given-names>PR</given-names></name><name><surname>Therneau</surname><given-names>TM</given-names></name><name><surname>Kyle</surname><given-names>RA</given-names></name><name><surname>Litzow</surname><given-names>MR</given-names></name><name><surname>Gertz</surname><given-names>MA</given-names></name></person-group><article-title>Autologous stem cell transplantation for relapsed and primary refractory myeloma</article-title><source>Bone Marrow Transplant</source><year>1999</year><volume>23</volume><fpage>1267</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1038/sj.bmt.1701805</pub-id><pub-id pub-id-type="pmid">10414914</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C-K</given-names></name><name><surname>Barlogie</surname><given-names>B</given-names></name><name><surname>Zangari</surname><given-names>M</given-names></name><name><surname>Fassas</surname><given-names>A</given-names></name><name><surname>Anaissie</surname><given-names>E</given-names></name><name><surname>Morris</surname><given-names>C</given-names></name><name><surname>Van Rhee</surname><given-names>F</given-names></name><name><surname>Cottler-Fox</surname><given-names>M</given-names></name><name><surname>Thertulien</surname><given-names>R</given-names></name><name><surname>Muwalla</surname><given-names>F</given-names></name><name><surname>Mazher</surname><given-names>S</given-names></name><name><surname>Badros</surname><given-names>A</given-names></name><name><surname>Tricot</surname><given-names>G</given-names></name></person-group><article-title>Transplantation as salvage therapy for high-risk patients with myeloma in relapse</article-title><source>Bone Marrow Transplant</source><year>2002</year><volume>30</volume><fpage>873</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/sj.bmt.1703715</pub-id><pub-id pub-id-type="pmid">12476279</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvares</surname><given-names>CL</given-names></name><name><surname>Davies</surname><given-names>FE</given-names></name><name><surname>Horton</surname><given-names>C</given-names></name><name><surname>Patel</surname><given-names>G</given-names></name><name><surname>Powles</surname><given-names>R</given-names></name><name><surname>Morgan</surname><given-names>GJ</given-names></name></person-group><article-title>The role of second autografts in the management of myeloma at first relapse</article-title><source>Haematologica</source><year>2006</year><volume>91</volume><fpage>141</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">16434386</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenk</surname><given-names>R</given-names></name><name><surname>Liese</surname><given-names>V</given-names></name><name><surname>Neubauer</surname><given-names>F</given-names></name><name><surname>Bruns</surname><given-names>I</given-names></name><name><surname>Kondakci</surname><given-names>M</given-names></name><name><surname>Balleisen</surname><given-names>S</given-names></name><name><surname>Saure</surname><given-names>C</given-names></name><name><surname>Schr&#x000f6;der</surname><given-names>T</given-names></name><name><surname>Haas</surname><given-names>R</given-names></name><name><surname>Kobbe</surname><given-names>G</given-names></name></person-group><article-title>Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation</article-title><source>Leuk Lymphoma</source><year>2011</year><volume>52</volume><fpage>1455</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.3109/10428194.2011.575967</pub-id><pub-id pub-id-type="pmid">21657961</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>G</given-names></name><name><surname>Liakopoulou</surname><given-names>E</given-names></name><name><surname>Pearce</surname><given-names>R</given-names></name><name><surname>Cavet</surname><given-names>J</given-names></name><name><surname>Morgan</surname><given-names>GJ</given-names></name><name><surname>Kirkland</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Davies</surname><given-names>FE</given-names></name><name><surname>Hall</surname><given-names>R</given-names></name><name><surname>Rahemtulla</surname><given-names>A</given-names></name><name><surname>Russell</surname><given-names>N</given-names></name><name><surname>Marks</surname><given-names>DI</given-names></name></person-group><article-title>Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry</article-title><source>Biol Blood Marrow Transplant</source><year>2011</year><volume>17</volume><fpage>1638</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2011.04.005</pub-id><pub-id pub-id-type="pmid">21565277</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jimenez-Zepeda</surname><given-names>VH</given-names></name><name><surname>Mikhael</surname><given-names>J</given-names></name><name><surname>Winter</surname><given-names>A</given-names></name><name><surname>Franke</surname><given-names>N</given-names></name><name><surname>Masih-Khan</surname><given-names>E</given-names></name><name><surname>Trudel</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Kukreti</surname><given-names>V</given-names></name><name><surname>Reece</surname><given-names>DE</given-names></name></person-group><article-title>Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival</article-title><source>Biol Blood Marrow Transplant</source><year>2012</year><volume>18</volume><fpage>773</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2011.10.044</pub-id><pub-id pub-id-type="pmid">22062804</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemieux</surname><given-names>E</given-names></name><name><surname>Hulin</surname><given-names>C</given-names></name><name><surname>Caillot</surname><given-names>D</given-names></name><name><surname>Tardy</surname><given-names>S</given-names></name><name><surname>Dorvaux</surname><given-names>V</given-names></name><name><surname>Michel</surname><given-names>J</given-names></name><name><surname>Gastinne</surname><given-names>T</given-names></name><name><surname>Rossi</surname><given-names>C</given-names></name><name><surname>Legouge</surname><given-names>C</given-names></name><name><surname>Touzeau</surname><given-names>C</given-names></name><name><surname>Planche</surname><given-names>L</given-names></name><name><surname>Loirat</surname><given-names>M</given-names></name><name><surname>Lafon</surname><given-names>I</given-names></name><name><surname>Moreau</surname><given-names>P</given-names></name></person-group><article-title>Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma</article-title><source>Biol Blood Marrow Transplant</source><year>2013</year><volume>19</volume><fpage>445</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2012.11.013</pub-id><pub-id pub-id-type="pmid">23186983</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sellner</surname><given-names>L</given-names></name><name><surname>Heiss</surname><given-names>C</given-names></name><name><surname>Benner</surname><given-names>A</given-names></name><name><surname>Raab</surname><given-names>MS</given-names></name><name><surname>Hillengass</surname><given-names>J</given-names></name><name><surname>Hose</surname><given-names>D</given-names></name><name><surname>Lehners</surname><given-names>N</given-names></name><name><surname>Egerer</surname><given-names>G</given-names></name><name><surname>Ho</surname><given-names>AD</given-names></name><name><surname>Goldschmidt</surname><given-names>H</given-names></name><name><surname>Neben</surname><given-names>K</given-names></name></person-group><article-title>Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients</article-title><source>Cancer</source><year>2013</year><volume>119</volume><fpage>2438</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1002/cncr.28104</pub-id><pub-id pub-id-type="pmid">23576287</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonsalves</surname><given-names>WI</given-names></name><name><surname>Gertz</surname><given-names>MA</given-names></name><name><surname>Lacy</surname><given-names>MQ</given-names></name><name><surname>Dispenzieri</surname><given-names>A</given-names></name><name><surname>Hayman</surname><given-names>SR</given-names></name><name><surname>Buadi</surname><given-names>FK</given-names></name><name><surname>Dingli</surname><given-names>D</given-names></name><name><surname>Hogan</surname><given-names>WJ</given-names></name><name><surname>Kumar</surname><given-names>SK</given-names></name></person-group><article-title>Second auto-SCT for treatment of relapsed multiple myeloma</article-title><source>Bone Marrow Transplant</source><year>2013</year><volume>48</volume><fpage>568</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1038/bmt.2012.183</pub-id><pub-id pub-id-type="pmid">23000647</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michaelis</surname><given-names>LC</given-names></name><name><surname>Saad</surname><given-names>A</given-names></name><name><surname>Zhong</surname><given-names>X</given-names></name><name><surname>Le-Rademacher</surname><given-names>J</given-names></name><name><surname>Freytes</surname><given-names>CO</given-names></name><name><surname>Marks</surname><given-names>DI</given-names></name><name><surname>Lazarus</surname><given-names>HM</given-names></name><name><surname>Bird</surname><given-names>JM</given-names></name><name><surname>Holmberg</surname><given-names>L</given-names></name><name><surname>Kamble</surname><given-names>RT</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Lill</surname><given-names>M</given-names></name><name><surname>Meehan</surname><given-names>KR</given-names></name><name><surname>Saber</surname><given-names>W</given-names></name><name><surname>Schriber</surname><given-names>J</given-names></name><name><surname>Tay</surname><given-names>J</given-names></name><name><surname>Vogl</surname><given-names>DT</given-names></name><name><surname>Wirk</surname><given-names>B</given-names></name><name><surname>Savani</surname><given-names>BN</given-names></name><name><surname>Gale</surname><given-names>RP</given-names></name><name><surname>Vesole</surname><given-names>DH</given-names></name><name><surname>Schiller</surname><given-names>GJ</given-names></name><name><surname>Abidi</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name><name><surname>Nishihori</surname><given-names>T</given-names></name><name><surname>Kalaycio</surname><given-names>ME</given-names></name><name><surname>Vose</surname><given-names>JM</given-names></name><name><surname>Moreb</surname><given-names>JS</given-names></name><name><surname>Drobyski</surname><given-names>W</given-names></name><name><surname>Munker</surname><given-names>R</given-names></name><etal/></person-group><article-title>Salvage second hematopoietic cell transplantation in myeloma</article-title><source>Biol Blood Marrow Transplant</source><year>2013</year><volume>19</volume><fpage>760</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2013.01.004</pub-id><pub-id pub-id-type="pmid">23298856</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auner</surname><given-names>HW</given-names></name><name><surname>Szydlo</surname><given-names>R</given-names></name><name><surname>Rone</surname><given-names>A</given-names></name><name><surname>Chaidos</surname><given-names>A</given-names></name><name><surname>Giles</surname><given-names>C</given-names></name><name><surname>Kanfer</surname><given-names>E</given-names></name><name><surname>Macdonald</surname><given-names>DH</given-names></name><name><surname>Marin</surname><given-names>D</given-names></name><name><surname>Milojkovic</surname><given-names>D</given-names></name><name><surname>Pavlu</surname><given-names>J</given-names></name><name><surname>Apperley</surname><given-names>JF</given-names></name><name><surname>Rahemtulla</surname><given-names>A</given-names></name></person-group><article-title>Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation</article-title><source>Leuk Lymphoma</source><year>2013</year><volume>54</volume><fpage>2200</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.3109/10428194.2013.773998</pub-id><pub-id pub-id-type="pmid">23387937</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh Abbi</surname><given-names>KK</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Devlin</surname><given-names>SM</given-names></name><name><surname>Giralt</surname><given-names>S</given-names></name><name><surname>Landau</surname><given-names>H</given-names></name></person-group><article-title>Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma</article-title><source>Biol Blood Marrow Transplant</source><year>2015</year><volume>21</volume><fpage>468</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2014.11.677</pub-id><pub-id pub-id-type="pmid">25529381</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fermand</surname><given-names>JP</given-names></name><name><surname>Ravaud</surname><given-names>P</given-names></name><name><surname>Chevret</surname><given-names>S</given-names></name><name><surname>Divine</surname><given-names>M</given-names></name><name><surname>Leblond</surname><given-names>V</given-names></name><name><surname>Belanger</surname><given-names>C</given-names></name><name><surname>Macro</surname><given-names>M</given-names></name><name><surname>Pertuiset</surname><given-names>E</given-names></name><name><surname>Dreyfus</surname><given-names>F</given-names></name><name><surname>Mariette</surname><given-names>X</given-names></name><name><surname>Boccacio</surname><given-names>C</given-names></name><name><surname>Brouet</surname><given-names>JC</given-names></name></person-group><article-title>High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial</article-title><source>Blood</source><year>1998</year><volume>92</volume><fpage>3131</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9787148</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barlogie</surname><given-names>B</given-names></name><name><surname>Kyle</surname><given-names>RA</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name><name><surname>Greipp</surname><given-names>PR</given-names></name><name><surname>Lazarus</surname><given-names>HM</given-names></name><name><surname>Hurd</surname><given-names>DD</given-names></name><name><surname>McCoy</surname><given-names>J</given-names></name><name><surname>Moore</surname><given-names>DF</given-names></name><name><surname>Dakhil</surname><given-names>SR</given-names></name><name><surname>Lanier</surname><given-names>KS</given-names></name><name><surname>Chapman</surname><given-names>RA</given-names></name><name><surname>Cromer</surname><given-names>JN</given-names></name><name><surname>Salmon</surname><given-names>SE</given-names></name><name><surname>Durie</surname><given-names>B</given-names></name><name><surname>Crowley</surname><given-names>JC</given-names></name></person-group><article-title>Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>929</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.04.5807</pub-id><pub-id pub-id-type="pmid">16432076</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atanackovic</surname><given-names>D</given-names></name><name><surname>Schilling</surname><given-names>G</given-names></name></person-group><article-title>Second autologous transplant as salvage therapy in multiple myeloma</article-title><source>Br J Haematol</source><year>2013</year><volume>163</volume><fpage>565</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1111/bjh.12579</pub-id><pub-id pub-id-type="pmid">24111632</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>G</given-names></name><name><surname>Williams</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>JM</given-names></name><name><surname>Cairns</surname><given-names>DA</given-names></name><name><surname>Cavenagh</surname><given-names>J</given-names></name><name><surname>Snowden</surname><given-names>JA</given-names></name><name><surname>Ashcroft</surname><given-names>AJ</given-names></name><name><surname>Fletcher</surname><given-names>M</given-names></name><name><surname>Parrish</surname><given-names>C</given-names></name><name><surname>Yong</surname><given-names>K</given-names></name><name><surname>Cavet</surname><given-names>J</given-names></name><name><surname>Hunter</surname><given-names>H</given-names></name><name><surname>Bird</surname><given-names>JM</given-names></name><name><surname>Chalmers</surname><given-names>A</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>S</given-names></name><name><surname>Drayson</surname><given-names>MT</given-names></name><name><surname>Morris</surname><given-names>TCM</given-names></name></person-group><article-title>High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><fpage>874</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(14)70245-1</pub-id><pub-id pub-id-type="pmid">24948586</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neben</surname><given-names>K</given-names></name><name><surname>Jauch</surname><given-names>A</given-names></name><name><surname>Bertsch</surname><given-names>U</given-names></name><name><surname>Heiss</surname><given-names>C</given-names></name><name><surname>Hielscher</surname><given-names>T</given-names></name><name><surname>Seckinger</surname><given-names>A</given-names></name><name><surname>Mors</surname><given-names>T</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>NZ</given-names></name><name><surname>Hillengass</surname><given-names>J</given-names></name><name><surname>Raab</surname><given-names>MS</given-names></name><name><surname>Ho</surname><given-names>AD</given-names></name><name><surname>Hose</surname><given-names>D</given-names></name><name><surname>Goldschmidt</surname><given-names>H</given-names></name></person-group><article-title>Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation</article-title><source>Haematologica</source><year>2010</year><volume>95</volume><fpage>1150</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.3324/haematol.2009.016436</pub-id><pub-id pub-id-type="pmid">20220069</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durie</surname><given-names>BGM</given-names></name><name><surname>Harousseau</surname><given-names>J-L</given-names></name><name><surname>Miguel</surname><given-names>JS</given-names></name><name><surname>Blad&#x000e9;</surname><given-names>J</given-names></name><name><surname>Barlogie</surname><given-names>B</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name><name><surname>Gertz</surname><given-names>M</given-names></name><name><surname>Dimopoulos</surname><given-names>M</given-names></name><name><surname>Westin</surname><given-names>J</given-names></name><name><surname>Sonneveld</surname><given-names>P</given-names></name><name><surname>Ludwig</surname><given-names>H</given-names></name><name><surname>Gahrton</surname><given-names>G</given-names></name><name><surname>Beksac</surname><given-names>M</given-names></name><name><surname>Crowley</surname><given-names>J</given-names></name><name><surname>Belch</surname><given-names>A</given-names></name><name><surname>Boccadaro</surname><given-names>M</given-names></name><name><surname>Cavo</surname><given-names>M</given-names></name><name><surname>Turesson</surname><given-names>I</given-names></name><name><surname>Joshua</surname><given-names>D</given-names></name><name><surname>Vesole</surname><given-names>D</given-names></name><name><surname>Kyle</surname><given-names>R</given-names></name><name><surname>Alexanian</surname><given-names>R</given-names></name><name><surname>Tricot</surname><given-names>G</given-names></name><name><surname>Attal</surname><given-names>M</given-names></name><name><surname>Merlini</surname><given-names>G</given-names></name><name><surname>Powles</surname><given-names>R</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Shimizu</surname><given-names>K</given-names></name><name><surname>Tosi</surname><given-names>P</given-names></name><name><surname>Morgan</surname><given-names>G</given-names></name><etal/></person-group><article-title>International uniform response criteria for multiple myeloma</article-title><source>Leukemia</source><year>2006</year><volume>20</volume><fpage>1467</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2404284</pub-id><pub-id pub-id-type="pmid">16855634</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blad&#x000e9;</surname><given-names>J</given-names></name><name><surname>Samson</surname><given-names>D</given-names></name><name><surname>Reece</surname><given-names>D</given-names></name><name><surname>Apperley</surname><given-names>J</given-names></name><name><surname>Bj&#x000f6;rkstrand</surname><given-names>B</given-names></name><name><surname>Gahrton</surname><given-names>G</given-names></name><name><surname>Gertz</surname><given-names>M</given-names></name><name><surname>Giralt</surname><given-names>S</given-names></name><name><surname>Jagannath</surname><given-names>S</given-names></name><name><surname>Vesole</surname><given-names>D</given-names></name></person-group><article-title>Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant</article-title><source>Br J Haematol</source><year>1998</year><volume>102</volume><fpage>1115</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2141.1998.00930.x</pub-id><pub-id pub-id-type="pmid">9753033</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The International Myeloma Working Group</collab></person-group><article-title>Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group</article-title><source>Br J Haematol</source><year>2003</year><volume>121</volume><fpage>749</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2141.2003.04355.x</pub-id><pub-id pub-id-type="pmid">12780789</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoenfeld</surname><given-names>D</given-names></name></person-group><article-title>The asymptotic properties of nonparametric tests for comparing survival distributions</article-title><source>Biometrika</source><year>1981</year><volume>68</volume><fpage>316</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/biomet/68.1.316</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Brien</surname><given-names>PC</given-names></name><name><surname>Fleming</surname><given-names>TR</given-names></name></person-group><article-title>A multiple testing procedure for clinical trials</article-title><source>Biometrics</source><year>1979</year><volume>35</volume><fpage>549</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.2307/2530245</pub-id><pub-id pub-id-type="pmid">497341</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fine</surname><given-names>JP</given-names></name><name><surname>Gray</surname><given-names>RJ</given-names></name></person-group><article-title>A proportional hazards model for the subdistribution of a competing risk</article-title><source>J Am Stat Assoc</source><year>1999</year><volume>94</volume><fpage>496</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1080/01621459.1999.10474144</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>JR</given-names></name><name><surname>Cain</surname><given-names>KC</given-names></name><name><surname>Gelber</surname><given-names>RD</given-names></name></person-group><article-title>Analysis of survival by tumor response</article-title><source>J Clin Oncol</source><year>1983</year><volume>1</volume><fpage>710</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">6668489</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durie</surname><given-names>BG</given-names></name><name><surname>Salmon</surname><given-names>SE</given-names></name></person-group><article-title>A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival</article-title><source>Cancer</source><year>1975</year><volume>36</volume><fpage>842</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(197509)36:3&#x0003c;842::AID-CNCR2820360303&#x0003e;3.0.CO;2-U</pub-id><pub-id pub-id-type="pmid">1182674</pub-id></element-citation></ref></ref-list></back></article>